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Summary
In this report, we present 15 patients with histological and immunopathologi-
cally proven pemphigus vulgaris (PV). After a mean of 80 months since the
onset of disease, when evaluated serologically, they had antibodies typical of
PV and pemphigoid (Pg). Similarly, 18 patients with bullous pemphigoid (BP)
and mucous membrane pemphigoid (MMP) were diagnosed on the basis of
histology and immunopathology.After amean of 60months since the onset of
disease, when their sera were evaluated they were found to have Pg and PV
autoantibodies. In both groups of patients the diseases were characterized by
a chronic course, which included several relapses and recurrences and were
non-responsive to conventional therapy. The major histocompatibility
complex class II (MHC II) genes were studied in both groups of patients
and phenotypes associated typically with them were observed. Hence,
in 33 patients, two different pathogenic autoantibodies were detected
simultaneously. The authors provide a computer model to show that each
MHC II gene has relevant epitopes that recognize the antigens associated with
both diseases. Using the databases in these computer models, the authors
present the hypothesis that these two autoantibodies are produced simulta-
neously due to the phenomena of epitope spreading.
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Introduction
Pemphigus vulgaris (PV) is a potentially fatal autoimmune
mucocutaneous blistering disease (AMBD) characterized by
flaccid blisters that can affect the skin and multiple mucous
membranes [1–4]. An intra-epidermal vesicle is seen on his-
tology, and the immunopathology is characterized by the
deposition of antibodies on the keratinocyte cell surfaces
[1–7]. The antigens are desmoglein 1 (Dsg 1) and desmo-
glein 3 (Dsg 3) [8], and possibly the acetylcholine receptor
[9]. The titres of serum autoantibodies may correlate with
disease activity and severity [8,10–12].
Pemphigoid (Pg) is principally a disease of the elderly and
is associated with a high mortality rate. It has two major
forms, bullous pemphigoid (BP) and mucous membrane
pemphigoid (MMP) [8]. BP affects the skin [4], while MMP,
also known as cicatricial pemphigoid (CP), affects predomi-
nantly the mucosa [2–4,6,7] and the skin [13,14]. The most
important difference between the two subsets of pemphigoid
is that when the blisters in MMP heal, they cause irreversible
scarring [14]. A subepidermal/subepithelial blister with an
infiltrate in the dermis or submucosa may be either pre-
dominantly eosinophilic, neutrophilic, or mixed [8,14,15].
The immunopathology shows deposition of immunoglobu-
lins and/or complement along the basement membrane zone
(BMZ) [4,8,14]. The target antigens in BP are desmoplakin-a
230 kDa protein also known as BP antigen 1 (BPAG 1) and a
hemidesmosome protein, also known as BP antigen 2 (BPAG
2) of 180 kDa [8,15]. Antibodies to both BPAG 1 and BPAG
2 are present in the sera of many patients with BP. In MMP,
ocular cicatricial pemphigoid (OCP) and oral pemphigoid
(OP), the reported antigens include BPAG 1, BPAG 2, human
integrin a6 and b4 and epiligrin [15–20]. Patients with anti-
bodies to epiligrin are referred to as anti-epiligrin cicatricial
pemphigoid (AECP), with antibodies against laminin 5 [21].
The majority of patients with AECP have solid tumours and
the mortality rate within the first 2 years is about 40–67%
[22,23] and are not included in this study.
The simultaneous presence of PV and either BP or CP in
the same patient has been reported by several authors
[4,8,24–39]. In this study, we present two groups of patients.
The first group consists of 15 patients who were diagnosed
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initially to have PV based upon histology and immuno-
pathology. However, when presenting at the Center for
Blistering Diseases (CBD) in Boston, their sera demon-
strated antibodies observed typically in both PV and Pg (BP
and/or CP), as tested by indirect immunofluorescence (IIF)
and enzyme-linked immunosorbent assay (ELISA). The
second group of 18 patients was diagnosed initially as having
BP or CP. When presenting at the CBD in Boston, their
serologies demonstrated antibodies typical of Pg but also of
antibodies seen in patients with PV.
The production of antibodies by B cells requires the coop-
eration of CD4 helper T cells and is delivered on the T cell
receptor (TCR)-mediated recognition of major histocom-
patibility complex class II (MHC II)-bound peptide antigens
(T cell epitopes) displayed on the cell surface of B cells [40].
These helper cell epitopes are derived from the same antigens
that are targeted by the antibodies after intracellular
processing. Similarly, pathogenic autoantibody production is
also contingent upon autoreactive CD4+ helper T cells rec-
ognizing T cell epitopes from self-antigens [41]. In this
context, the purpose of this study was to characterize the
autoantibody profile in the two mentioned groups of
patients, to determine the human leucocyte antigen class II
(HLA II) – MHC II – genes and to identify potential autore-
active helper T cell epitopes that might be shared across
disease models.
Methods
Patients
The patients in this study have not been reported in any
earlier publications. These patients were seen between
March 2005 and November 2009 at the Center for Blister-
ing Diseases (CBD) in Boston. Institutional Review Board
(IRB) approval was obtained to conduct the study. Written
consent was obtained from each patient. It is important to
highlight that, in all the patients, the initial diagnosis was
made considerably earlier than their evaluation at the CBD.
They were referred to the CBD because, in spite of high-
dose long-term systemic corticosteroids and the use of
multiple systemic immunosuppressive agents used over a
period of several months or years, their diseases were not
controlled and a sustained clinical remission had never
been achieved. Hence, in these patients, the disease was
chronic and characterized by multiple recurrences and
relapses.
Inclusion criteria
1. At the time of initial diagnosis, the patients had histology,
confirmed by direct immunofluorescence for PV, BP and
CP.
2. The duration between the initial diagnosis and the time at
presentation to the CBD was available.
3. Careful history of drugs being taken by each patient was
obtained. Patients who were on medications that are
known to be associated with triggering either PV or Pg
were not included.
4. All these patients were referred to CBD for clinical man-
agement of recurrent disease. The presence of antibodies
for two diseases occurring simultaneously was confirmed
in each patient on serological evaluation at three different
time intervals.
Serological analysis
Indirect immunofluorescence. The sera of the patients in
both groups was evaluated by indirect immunofluorescence
(IIF) using monkey oesophagus as substrates which mea-
sured the titres of the intercellular cement substance (ICS)
antibodies and BMZ antibodies. Simultaneously, in both
groups, antibodies to Dsg 1, Dsg 3, BPAG 1 and BPAG 2 were
measured by an ELISA [12,42–44]. The index values for the
ELISAs are as follows: for Dsg 1, fewer than 14 is negative,
9–20 is intermediate and greater than 20 is positive. The
index values for Dsg 3 are: fewer than nine is negative, 9–20
is intermediate, and greater than 20 are positive. The index
values of BPAG1 and BPAG2 are identical and as follows:
fewer than nine is negative and greater than nine is positive.
These serological tests were performed by laboratories at
hospitals from where patients were referred, and some by
Beutner Laboratories, Buffalo, NY.
HLA class II genes
HLA II genes encoded by the DRb1 and DQb1 loci were
identified by polymerase chain reaction (PCR) with
sequence-specific primers (PCR-SSP), as described previ-
ously [45], and were performed by laboratories in the insti-
tutions from where the patients were referred and some by
the American Red Cross, HLA Laboratory in Dedham, MA.
Molecular analysis of the MHC II genes and their
potential sites to bind to relevant antigens
Because T cell immune responses are triggered by MHC-
bound peptide antigens (T cell epitopes), prediction of
peptide-MHC binding is a basis to anticipate T cell epitopes
[46]. MHC molecules bind peptides with a shared sequence
similarity due to their binding pocket restrictions. Therefore,
in this study we have position-specific scoring matrix
(PSSMs), derived from epitopes that are known to bind to
specific HLA II molecules [47–49], to predict potential T cell
epitopes within the antigens of interest. T cell epitope pre-
dictions using PSSMs were executed using the rankpep
server (http://imed.med.ucm.es/Tools/rankpep.html). Only
those peptides that received scores above the binding thresh-
old (BT) were considered to bind to the relevant HLA II
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molecule. Each PSSM has a specific BT that was defined after
computing the binding scores of the same peptide epitopes
used to derive them; ~85% of epitopes that are known to
bind to a given MHCmolecule receive a binding score that is
above the BT. Details are reported by Reche et al. [47–49].
Results
Group 1
Patients with PV as initial diagnosis and subsequently having
antibodies to PV and Pg antigens. These data are presented in
Table 1. Patients in this group had a diagnosis of PV based on
histology and direct immunofluorescence at the time of
initial evaluation. When evaluated at CBD their sera con-
tained antibodies to PV and Pg antigens. This group con-
sisted of 15 patients: eight males and seven females. Ages
ranged from 23 to 83 (mean 54·23). All patients were
Caucasians. Eight patients had only mucosal disease and
seven patients had mucocutaneous disease. The interval
between the time of the initial histological and immunologi-
cal diagnosis and the serological detection of two antibodies
was 2–146 months (mean 80 months).
Serological testing demonstrated the following results:
1. On IIF, all patients had antibodies to the keratinocyte
surface. The titres varied from 80 to 640.
2. On IIF, all the patients had high levels of anti-BMZ
antibodies. The sera of all the patients bound only to the
epidermal side of the basement membrane on salt split
skin (SSS).
3. The ELISA for Dsg 1 was positive in seven of the 15
patients and Dsg 3 in all 15 patients.
4. The ELISA for BPAG 2 was positive in 15 patients.
Group 2
Patients diagnosed initially as Pg and subsequently demon-
strating antibodies to both Pg and PV antigens. These data are
presented in Table 2. Patients in this group had an initial
diagnosis of Pg (BP/MMP) based on histology and direct
immunofluorescence at the time of initial evaluation. When
evaluated at the CBD, their sera demonstrated the presence
of antibodies to both Pg and PV antigens. Seven patients had
BP and 11 patients had MMP (four males and 14 females).
The ages ranged from 28 to 91 (mean 64·94). All patients
were Caucasians. Five patients had only cutaneous disease,
six had only mucosal disease and seven had mucocutaneous
disease. The interval between the immunopathological diag-
nosis of Pg and the date of the serology demonstrating the
presence of two antibodies was 10–151 months (mean 60
months).
Serological testing demonstrated the following results:
Table 1. Characterization of pemphigus vulgaris (PV) patients with antibodies to PV and pemphigoid (Pg).
Group 1
Demographics
Serological studies HLA
Anti-ICS Anti-BMZ MHC II
Ind. IF ELISA Ind. IF ELISA 1st haplotype 2nd haplotype
Patient Age Sex C.P. Int. IgG Dsg 1 Dsg 3 IgG BP1 BP2 DRB1 DQB1 DRB1 DQB1
PV1 83 F MuCu 97 160 110 167 80 17 20 1401 0503 1101 0301
PV2 53 F MuCu 82 640 165 369 40 4 26 1454 0503 0302 0402
PV3 62 M MuCu 115 1260 115 236 40 56 12 1454 0503 0402 0302
PV4 56 M Mu 146 320 6 193 80 60 58 0402 0302 1301 0603
PV5 23 M MuCu 72 640 15 201 40 n.d. 20 0402 0302 1101 0301
PV6 68 M Mu 81 640 19 63 20 25 28 1401 0503 1101 0301
PV7 24 F MuCu 84 640 97 148 20 n.d. 13 1401 0503 1101 0301
PV8 67 M MuCu 75 160 107 166 20 n.d. 19 0402 0302 1104 0301
PV9 54 F Mu 36 160 14 143 20 11 21 0801 0503 1104 0301
PV10 60 F Mu 101 160 132 25 20 4 17 0402 0302 1304 0201
PV11 63 M Mu 94 320 24 171 40 15 26 0402 0302 0102 0501
PV12 54 F Mu 57 640 12 127 40 9 21 1454 0503 1301 0502
PV13 38 M Mu 2 160 20 29 40 n.d. 14 0301 0201 1501 0602
PV14 47 F Mu 16 640 11 141 20 14 19 0402 0302 1302 0602
PV15 39 M MuCu 28 5120 17 158 20 25 18 0402 0302 1001 0501
Dsg 1 enzyme-linked immunosorbent assay (ELISA) index values [44]: < 14 = negative; 14–20 = indeterminate; > 20 = positive. Dsg 3 ELISA index
values [44]: < 9 = negative; 9–20 = indeterminate; > 20 = positive. BP1 and BP2 index values [42,43]: < 9 = negative; > 9 = positive. Ind. IF: indirect
immunofluorescence;M:male; F: female; J: Jewish; NJ: non-Jewish;Mu:mucous membrane;MuCu:mucocutaneous; BP1: BP antigen 1 (230 kDa); BP2:
BP antigen 2 (180 kDa); CP: clinical profile; Dsg: desmoglein; Int.: time interval in weeks; n.d.: not done; IgG: immunoglobulin G; HLA: human
leucocyte antigen; MHC: major histocompatibility complex; ICS: intercellular cement substance; BMZ: basement membrane zone.
MHC class II genes and two autoantibodies
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1. On IIF, the sera of all 17 patients were positive for anti-
BMZ antibodies. The sera of all the patients bound only
to the epidermal side of the basement membrane on SSS.
2. The ELISA BPAG 1 was positive in eight of 18 patients,
not performed in 18 patients and negative in the remain-
ing six of 18 patients. For BPAG 2, the ELISA was positive
for 18 patients.
3. On IIF, all patients had antibodies to the keratinocyte
surface; the titre varied from 20 to 160.
4. The ELISA for Dsg 1 and/or Dsg 3 was positive in 16 of 18
patients, and two of 18 had indeterminate levels.
Indirect immunofluorescence results using monkey
oesophagus as substrate are presented in Fig. 1 as a prototype
example. Figure 1a represents binding of PV sera to kerati-
nocyte cell surface antigens. Figure 1b represents BP or CP
antibodies binding to BMZ. Figure 1c represents a sera in
which antibodies to PV bind to ICS and antibodies to BP or
CP bind to BMZ simultaneously. The binding to the kerati-
nocyte cell surface is brighter because the antibody titre may
be higher and the binding is sharp and defined.
Immunogenetic studies
Only patients, not families, were studied. Although the data
are phenotypic, the results are expressed as presumed hap-
lotypes because of their known associations based upon
linkage disequilibrium.
Group 1: patients with PV as initial diagnosis and subsequently
having antibodies to PV and Pg antigens. High-resolution
MHC II gene analysis by PCR-SSP demonstrated that nine
patients had HLA-DRb1*0402 and seven patients had HLA-
DQb1*0503. Also, one patient carried only the PV HLA
genes but no Pg genes; one patient did not carry any gene
associated with PV, but had the DQb1*0301 and DQb1*0602
associated with Pg.
In the same patients, MHC II genes associated with Pg
were observed on the second haplotype. HLA-DQb1*0301
was present in seven patients. HLA-DQb1*0302 was present
in nine patients, HLA-DQb1*0603 was present in one
patient and HLA-DQb1*0602 was present in two patients.
Group 2: patients diagnosed initially as Pg and subsequently
demonstrating antibodies to both Pg and PV antigens. High-
resolution MHC II gene analysis by PCR-SSP demonstrated
that 15 patients carried DQb1*0301 on one haplotype. One
patient carried DQb1*0302, and two carried DQb1*0602.
Also, five patients were homozygous for DQb1*0301.
In the same patients, MHC II genes associated with PV
were observed on the second haplotype. Seven patients
Table 2. Characterization of pemphigoid (Pg) patients with antibodies to (pemphigoid (Pg) and pemphigus vulgaris (PV).
Group 2
Demographics
Serological studies HLA
Anti-ICS Anti-BMZ MHC II
Ind. IF ELISA Ind. IF ELISA 1st haplotype 2nd haplotype
Patient Age Sex CP Int. IgG Dsg 1 Dsg 3 IgG BP1 BP2 DRB1 DQB1 DRB1 DQB1
BP1 91 M Cu 16 40 18 26 640 18 13 0701 0202 1501 0602
BP2 79 F Cu 72 40 25 15 160 n.d. 14 1104 0301 1101 0301
BP3 86 F Cu 32 160 11 17 80 3 18 1101 0301 1104 0301
BP4 49 F MuCu 79 20 23 2 1280 15 20 0701 0202 1301 0501
BP5 82 M Cu 59 160 27 4 640 4 27 1104 0301 1101 0301
BP6 80 F MuCu 10 40 13 31 80 16 37 1303 0301 1104 0301
BP7 69 F Cu 36 20 16 29 40 12 132 1001 0501 0404 0302
CP1 28 F Mu 42 160 32 65 20 18 n.d. 0901 0202 0404 0301
CP2 56 F Mu 144 80 27 29 40 3 18 1104 0301 1101 0301
CP3 41 F MuCu 151 160 18 26 40 18 13 1401 0503 0407 0301
CP4 57 F Mu 66 20 23 34 40 n.d. 14 1501 0602 0401 0301
CP5 79 M MuCu 62 20 18 20 40 4 20 0101 0503 0401 0301
CP6 67 F MuCu 42 40 21 36 40 36 44 1401 0503 0404 0301
CP7 72 M Mu 75 40 40 59 20 7 21 0101 0503 0401 0301
CP8 55 F Mu 41 40 19 23 20 n.d. 28 0101 0503 1101 0301
CP9 47 F MuCu 29 20 23 29 640 71 18 0101 0503 1201 0301
CP10 66 F Mu 61 20 13 30 40 n.d. 24 1404 0503 1101 0301
CP11 52 F MuCu 18 20 22 30 20 4 27 0103 0501 1101 0301
Dsg 1 enzyme-linked immunosorbent assay (ELISA) index values [44]: < 14 = negative; 14–20 = indeterminate; > 20 = positive. Dsg 3 ELISA index
values [44]: < 9 = negative; 9–20 = indeterminate; > 20 = positive. BP1 and BP2 index values [42,43]: < 9 = negative; > 9 = positive. Ind. IF: indirect
immunofluorescence; M: male; F: female; J: Jewish; NJ: non-Jewish; Mu; mucous membrane; MuCu: mucocutaneous; Cu, Cutaneous; BP1, BP Antigen
1 (230 kDa); BP2, BP Antigen 2 (180 kDa); CP: clinical profile; Dsg: desmoglein; Int.: time interval in weeks; n.d.: not done; IgG: immunoglobulin G;
HLA: human leucocyte antigen; MHC: major histocompatibility complex; ICS: intercellular cement substance; BMZ: basement membrane zone.
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carried DQb1*0503 and those same seven patients also
carried DQb1*0301 on the second haplotype. None of the
patients carried DRb1*0402. Six patients carried only Pg
genes but no PV genes. One patient did not carry any genes
known to be associated with either PV or Pg.
Molecular analysis of the MHC II genes and their
potential sites to bind to relevant antigens
The HLA II alleles associated with PV and Pg and the rel-
evant antigens, when subjected to the rankpep program,
demonstrate that there are potential T cell epitopes within
BPAG 2 (Fig. 2a) and a6 integrin (Fig. 2b) that are predicted
to bind to DRb1*0402. For purposes of brevity only BPAG 2
and a6 data are presented, but these observations would be
applicable to BPAG 1 and b4 integrin.When subjected to the
rankpep program, there are potential T cell epitopes within
Dsg 3 that are predicted to bind to DQb1*0301 and
DRb1*0402, as presented in Fig. 2c.
Discussion
In this report we present 15 patients with a clinically, histo-
logically and immunopathologically established diagnosis of
PV.After a mean of 80 months following the initial diagnosis
with persistent disease, when evaluated serologically patients
demonstrated the presence of antibodies seen typically in PV
patients, and in association with antibodies seen in patients
with Pg. Similarly, we report a group of 18 patients with a
clinical, histological and immunopathologically established
diagnosis of Pg. After a mean period of 60 months with
clinically active disease, their sera demonstrated presence of
antibodies seen in Pg and in association with antibodies seen
typically in PV. Thus, these patients could be labelled as
having a dual diagnosis. The PV, BP and CP patients had
long-term chronic disease characterized by repeated exacer-
bations and relapses. Hence, it appears that these patients are
a distinct subset of patients in both disease groups, their
distinctive features being chronicity of disease, recurrent
relapses and remissions and lack of response to conventional
therapy. Several patients are described in the literature who
had PV and Pg simultaneously [8].
The patients in group 1 have the MHC II genes
DRb1*0402 and DQb1*0503 that have been reported in
patients with PV in several studies [50–66]. Many of these
patients also had the MHC II genes associated with patients
with Pg, which is DQb1*0301. However, because of amino
acid sequence homology in the critical 71–77 positions of the
DQb1 gene, it has been demonstrated that DQb1*0302,
DQb1*0303, DQb1*0305, DQb1*0602 and DQb1*0603
have largely overlapping peptide-binding repertoires and,
thus, may have shared epitopes within Pg [67].
In group 2, there were 18 patients with subsets of MMP
and BP, all of which are characterized by in-vivo deposition
of anti-BMZ antibodies on direct immunofluorescence.
These patients had MHC II gene HLA-DQb1*0301 that is
observed typically in patients with all the variants of Pg
[16,67–74]. In addition,many of these patients also carry the
MHC II genes associated typically with PV patients.
While the authors recognize completely that there could
be several reasons that could account for these unique obser-
vations, the current data would suggest that one of the vari-
ables may be immunogenetically based. The presence of
haplotypes or alleles associated with PV and Pg simulta-
neously in the same patient have been reported previously in
several studies [16,52,53,55,61,64,67,69,75–77]. The alleles
and haplotypes known to be associated with PV are
DRb1*0402/DQb1*0302 and DRb1*1401/DQb1*05031.
In one study there were several patients with these
PV-associated haplotypes or phenotypes that also carried
DQb1*0301 on the second haplotype [76]. In another study,
two of nine PV patients had DQb1*0301 on the second
haplotype, and this frequency was higher than in the control
population [55]. In three of 10 patients with PV,DQb1*0301
was present and all these patients had predominantly
mucosal diseases [77]. Similarly, several studies on Pg which
included OP, OCP, MMP and BP show that while patients
carry the DQb1*0301 allele, they often carry DRb1*0402
or DQb1*0503 on the second haplotype [16,64,67]. Inter-
estingly, in some studies the frequency of DRb1*04 is
Fig. 1. Indirect immunofluorescence using monkey oesophagus as
substrate. (a) Binding of sera of a pemphigus vulgaris (PV) patient to
intercellular cement substance (ICS) (keratinocyte cell surface)
(indicated by the white arrows). (b) Binding of sera of a pemphigoid
(Pg) patient to basement membrane zone (BMZ) (indicated by the
white arrows). (c) Binding of the sera of a patient with dual diagnosis
to both BMZ and ICS (indicated by the white arrows).
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statistically significantly increased in Pg patients on the same
haplotype as DQb1*0301 [53,69]. Unfortunately, however,
high- resolution typing of DRb1*04 was not performed
[53,69]. Should the DRb1*04 be DRb1*0402, it would have
readily explained the presence of alleles linked strongly to
PV. Another major handicap of these studies is that the
authors did not study or report the presence of pathogenic
autoantibodies to PV or Pg in their reports.
There are several reports in the literature to indicate that
patients with PV and Pg have been associated with several
other autoimmune diseases. BP has been reported in patients
with systemic lupus erythematosus (SLE), rheumatoid
arthritis (RA), Sjögren’s syndrome, myasthenia gravis (MG)
and multiple sclerosis (MS) [78–89]. MMP has been
reported in patients with SLE, connective tissue disease
(CTD) and RA [90–95]. Also, PV has been reported with
SLE, CTD, MS, MG, alopecia universalis, insulin-dependent
diabetes mellitus, autoimmune thyroid disease, Sjögren’s
syndrome and systemic sclerosis [96–113].
There are numerous examples in the literature of patients
with one autoimmune disease who, during the course
of their illness, develop a second autoimmune disease
[89,114–131].
Epitope spreading provides four possible scenarios that
may explain the presence of two simultaneous pathogenic
autoantibodies in one patient. The first scenario may be that
one large antigen molecule may contain at least two epitopes
that have a certain degree of similarity or overlapping
sequence [132]. However, when presented by two different
MHC II genes, they stimulate two different T cells and result-
antly activate two different B cells through CD40–CD40L
interaction. These B cells then produce two different
autoantibodies. The second scenario may be that antigen-
presenting cells (APC), internalizing two separate antigens,
then activate two different T cells that are specific to any one
of these antigens [132–134]. The third scenario may be that
two antigens are clustered in a single macromolecule
complex, all of which are internalized by a single APC
[132,135–137]. This APC then activates two different T cells,
making each specific for one subset of the macromolecule.
The T cells would then enlist B cells and result in the pro-
duction of two different autoantibodies. Finally, the fourth
scenario may be that an autoimmune disease causes tissue
damage and inflammation in the surrounding tissue
[132,138,139]. This exposes the immune system to a previ-
ously sequestered epitope. This epitope becomes internalized
by an APC, presented to a T cell that enlists B cells and
produces a second antibody. It has been demonstrated in
patients with Stevens–Johnson syndrome that when there is
extensive inflammation and tissue damage, patients often
develop OCP [140]. Moreover, it has been found that MHC
II genes are important in influencing the type of antibodies
and the amount produced [141]. Furthermore, recent
studies indicate that the perfect fitting of the core nonameric
peptide residues within the binding groove within the MHC
II alleles are not capable of guaranteeing a complete fitting of
the entire peptide [52]. Indeed, flanking residues outside the
binding groove could also play an important role in the
selection of the peptide [52]. Based on the studies by Reche
et al., using the rankpep program, we have shown that PV
and Pg antigens may potentially bind both the DRb1*0402
and DQb1*0301 genes to stimulate an immune response
(Fig. 2a–c). Therefore, within the four scenarios, it is theo-
retically possible for a patient with only DRb1*0402 to
produce anti-BMZ antibodies if epitope spreading occurred
to a Pg antigen, and the same is possible for DQb1*0301and
anti-ICS antibodies. Collectively, those hypothetical models
would lead to the conclusion that key determinants in one
patient producing two autoantibodies would lie in the
molecular structure of the antigen and binding properties of
theMHC II gene products. That said, the specificity of T cells
to recognize specific epitopes and enlist B cells that produce
only a specific autoantibody is a necessary corollary. While
the authors do not claim that this may be the only mecha-
nism to explain their observations, they are highlighting the
above primarily because of the availability of these data and
their possible utilization in providing an explanation. It is
also possible that the production of two antibodies in the
same patient could occur as a consequence of other genetic
factors or non-genetic factors that have yet to be identified or
described. The authors have highlighted the genetic factors
because all these patients are unrelated.
While definitive experiments showing T cell proliferation
are not performed in this study, there are preliminary reports
in the literature to show that when homozygous typing cell
lines that carry DQb1*0301 are used for the purpose of
antigen presentation, T cells from PV patients proliferate
when stimulated with Dsg 3 peptides [75]. This is evidence
that the DQb1*0301 molecule, with Dsg 3, has the potential
to give rise to or facilitate the process that can produce PV
antibodies.
The importance of these observations is both clinical and
biological. These studies provide a unique opportunity to
demonstrate that, in rare instances when individuals inherit
genes associated with enhanced susceptibility to developing
an autoimmune disease, trigger(s) can activate the immune
system to respond unfavourably and produce two
autoantibodies. Such patients can have a chronic form of the
disease that is recalcitrant to conventional therapy. The clini-
cal scenarios presented pose a significant problem to the
patient and the treating physician.
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